AstraZeneca Reports Data from the P-III (WAYPOINT) Study of Tezspire (Tezepelumab) for Chronic Rhinosinusitis with Nasal Polyps
Shots:
- The P-III (WAYPOINT) study is assessing the safety & efficacy of Tezspire (SC) vs PBO to treat adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for 52wks., followed by a post-treatment follow-up duration of 12-24wks.
- Study depicted a significantly reduced size of nasal polyps & decreased nasal congestion, with the safety & tolerability aligning with prior findings. Details will be shared with the regulatory authorities & highlighted at future conferences
- Tezspire, being developed by AZ & Amgen, is a human mAb that works by inhibiting TSLP activity which is responsible for allergic, eosinophilic & other types of endothelial inflammation related to severe asthma and other inflammatory diseases
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
